Area of research
Pulmonary and Respiratory Medicine · Radiation
Research interest
Dr. Teh’s research focuses on the treatment of genito-urinary malignancies and unlocking the myth of radio-resistance in cancers especially renal cell carcinoma. Other research interests include Intensity modulated radiation therapy (IMRT) for prostate cancer, head and neck cancer, central nervous system tumor, pediatric cancer and breast cancer, stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), stereotactic radiation therapy (SRT) and image-guided radiation therapy (IGRT), brachytherapy for prostate cancer, breast cancer and endobronchial tumors, SRS and SBRT for primary and metastatic renal cell carcinoma as well as hepatocellular carcinoma, the role of combined radiotherapy and gene therapy for cancers including prostate cancer, renal cell carcinoma, bladder cancer
Distinguishing Benign Notochordal Cell Tumors From Chordoma in a Patient With Multicentric Spinal Lesions.
Evaluating Adjuvant Radiation Therapy Survival Benefit in Early-Stage HER2-Positive Invasive Breast Cancer Following Breast-Conserving Surgery: A National Cohort Aligned with NRG-BR008 HERO Trial.
A Case of Physiologic Enhancement of Scarpa's Ganglia Mimicking Bilateral Vestibular Schwannomas in a Patient With Atypical Meningioma With NF2 Mutation.
Data from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Data from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Figure from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Figure from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Figure from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Supplementary Figure from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.
Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer.
Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1
Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma.
Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma
Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma
Consensus guidelines for postoperative stereotactic body radiation therapy for spinal metastases: results of an international survey
Consensus Statement from the International Radiosurgery Oncology Consortium for Kidney for Primary Renal Cell Carcinoma